Calcium sensitizers: What have we learned over the last 25 years?

International Journal of Cardiology

Volumn 203, Issue , 2016, Pages 543-548

  Pollesello, P ^a   Papp, Z ^b   Papp, J Gy ^c  

^a Orion Pharma   (Finland)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Cardiovascular pharmacology; Heart failure; Inodilators; Inotropes; Myosin; Troponin C

Indexed keywords

CALCIUM SENSITIZER; LEVOSIMENDAN; MYOSIN; OMECAMTIV; PIMOBENDAN; TROPONIN C; UNCLASSIFIED DRUG; CALCIUM; CALCIUM INTAKE; CARDIOTONIC AGENT;

DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; HEART ATRIUM ARRHYTHMIA; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOTENSION; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; CALCIUM INTAKE; DRUG EFFECTS; HEART CONTRACTION; HEMODYNAMICS; METABOLISM; PATHOPHYSIOLOGY; THERAPEUTIC USE;

CALCIUM; CALCIUM, DIETARY; CARDIOTONIC AGENTS; HEART FAILURE; HEMODYNAMICS; HUMANS; MYOCARDIAL CONTRACTION;

EID: 84952685283     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.10.240     Document Type: Review

References (80)

1. J.S. Forrester, and D.D. Waters Hospital treatment of congestive heart failure. Management according to hemodynamic profile Am. J. Med. 65 1 1978 173 180
2. W.B. Van Winkle, and A. Schwartz Ions and inotropy Annu. Rev. Physiol. 38 1976 247 272
3. S. Ringer A further contribution regarding the influence of the different constitutes of the blood on the contraction of the heart J. Physiol. Lond. 4 1883 29 42
4. R.M. Gunnar, H.S. Loeb, M. Klodnycky, M.Z. Sinno, and W. Towne Hemodynamic effects of dobutamine in man Circulation 48 1973 523
5. J.R. Benotti, W. Grossman, E. Braunwald, D.D. Davolos, and A.A. Alousi Hemodynamic assessment of amrinone. A new inotropic agent N. Engl. J. Med. 299 25 1978 1373 1377
6. R.C. Dage, L.E. Roebel, C.P. Hsieh, D.L. Weiner, and J.K. Woodward Cardiovascular properties of a new cardiotonic agent: MDL 17,043 (1.3-dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol-2-one) J. Cardiovasc. Pharmacol. 4 3 1982 500 508
7. C.S. Maskin, L. Sinoway, B. Chadwick, E.H. Sonnenblick, and T.H. Le Jemtel Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure Circulation 67 5 1983 1065 1070
8. L. Nagy, P. Pollesello, and Z. Papp Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus J. Cardiovasc. Pharmacol. 64 3 2014 199 208
9. P.V. Sulakhe, and X.T. Vo Regulation of phospholamban and troponin-I phosphorylation in the intact rat cardiomyocytes by adrenergic and cholinergic stimuli: roles of cyclic nucleotides, calcium, protein kinases and phosphatases and depolarization Mol. Cell. Biochem. 149-150 1995 103 126
10. J. Wattanapermpool, X. Guo, and R. Solaro The unique amino-terminal peptide of cardiac troponin-i regulates myofibrillar activity only when it is phosphorylated J. Mol. Cell. Cardiol. 27 7 1995 1383 1391
11. P. Han, W. Cai, Y. Wang, C.K. Lam, D.A. Arvanitis, V.P. Singh, and et al. Catecholaminergic-induced arrhythmias in failing cardiomyocytes associated with human HRCS96A variant overexpression Am. J. Physiol. Heart Circ. Physiol. 301 4 2011 H1588 H1595
12. C.-C. Chou, S. Zhou, H. Hayashi, M. Nihei, Y.-B. Liu, M.-S. Wen, and et al. Remodelling of action potential and intracellular calcium cycling dynamics during subacute myocardial infarction promotes ventricular arrhythmias in Langendorff-perfused rabbit hearts J. Physiol. 580 Pt 3 2007 895 906
13. E.G. Lakatta Cardiovascular regulatory mechanisms in advanced age Physiol. Rev. 73 2 Apr 1993 413 467
14. T. Kono, H.N. Sabbah, H. Rosman, H. Shimoyama, M. Alam, and S. Goldstein Divergent effects of intravenous dobutamine and nitroprusside on left atrial contribution to ventricular filling in dogs with chronic heart failure Am. Heart J. 127 4 Pt 1 1994 874 880
15. C.L. Tacon, J. McCaffrey, and A. Delaney Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials Intensive Care Med. 38 2012 359 367
16. P. Nony, J.P. Boissel, M. Lievre, A. Leizorovicz, M.C. Haugh, S. Fareh, and et al. Evaluation of the effect of phosphodiestherase inhibitors on mortality in chronic heart failure patients. A meta-analysis Eur. J. Clin. Pharmacol. 46 1994 191 196
17. R.J. Solaro, and J.C. Rüegg Stimulation of Ca ++ binding and ATPase activity of dog cardiac myofibrils by AR-L 115BS, a novel cardiotonic agent Circ. Res. 51 3 Sep 1982 290 294
18. 2 + sensitivity of contractile proteins Circulation 73 3 Pt 2 Mar 1986 III78 III84
19. M.J. Holroyde, S.P. Robertson, J.D. Johnson, R.J. Solaro, and J.D. Potter The calcium and magnesium binding sites on cardiac troponin and their role in the regulation of myofibrillar adenosine triphosphatase J. Biol. Chem. 255 24 1980 11688 11693
20. J.C. Rüegg, G. Pfitzer, D. Eubler, and C. Zeugner Effect on contractility of skinned fibres from mammalian heart and smooth muscle by a new benzimidazole derivative, 4,5-dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methy l-3(2H)-pyridazinone Arzneimittelforschung 34 12 1984 1736 1738
21. 2 + sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study J. Biol. Chem. 269 46 1994 28584 28590
22. K. Kato Clinical efficacy and safety of pimobendan in treatment of heart failure-experience in Japan Cardiology 88 Suppl. 2 1997 28 36
23. M.S. Nieminen, S. Fruhwald, L.M. Heunks, P.K. Suominen, A.C. Gordon, M. Kivikko, and et al. Levosimendan: current data, clinical use and future development Heart Lung Vessel. 5 4 2013 227 245
24. H. Scholz, and W. Meyer Phosphodiesterase-inhibiting properties of newer inotropic agents Circulation 73 3 Pt 2 Mar 1986 III99 II108
25. G.W. Smith, J.C. Hall, and P.A. West Lack of inotropic selectivity of phosphodiestherase enzyme inhibitors in-vitro J. Pharm. Pharmacol. 39 9 Sep 1987 748 751
26. Z. Papp, I. Édes, S. Fruhwald, S.G. De Hert, M. Salmenperä, H. Leppikangas, and et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan Int. J. Cardiol. 159 2 Aug 23 2012 82 87
27. B.P. Morgan, A. Muci, P.P. Lu, X. Qian, T. Tochimoto, W.W. Smith, and et al. Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac myosin ACS Med. Chem. Lett. 1 9 2010 472 477
28. F.I. Malik, J.J. Hartman, K.A. Elias, B.P. Morgan, H. Rodriguez, K. Brejc, and et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure Science 331 6023 2011 1439 1443
29. J.G. Cleland, J.R. Teerlink, R. Senior, E.M. Nifontov, J.J. Mc Murray, C.C. Lang, and et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial Lancet 378 9792 Aug 20 2011 676 683
30. A. Fitton, and R.N. Brogden Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure Drugs Aging 4 5 1994 417 441
31. M. Walter, I. Liebens, H. Goethals, M. Renard, A. Dresse, and R. Bernard Pimobendane (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic cross-over and double-blind study with two different doses Br. J. Clin. Pharmacol. 25 3 1988 323 329
32. J. Lubsen, H. Just, A.C. Hjalmarsson, D. La Framboise, W.J. Remme, J. Heinrich-Nols, and et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial Heart 76 3 1996 223 231
33. H. Haikala, and I.B. Linden Mechanisms of action of calcium-sensitizing drugs J. Cardiovasc. Pharmacol. 26 Suppl. 1 1995 S10 S19
34. H. Haikala, J. Kaivola, E. Nissinen, P. Wall, J. Levijoki, and I.B. Linden Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan J. Mol. Cell. Cardiol. 27 1995 1859 1866
35. 2+-sensitization Eur. J. Pharmacol. 486 2004 1 8
36. J. Levijoki, P. Pollesello, J. Kaivola, C. Tilgmann, T. Sorsa, A. Annila, and et al. Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan J. Mol. Cell. Cardiol. 32 2000 479 491
37. T. Sorsa, P. Pollesello, and R.J. Solaro The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c Mol. Cell. Biochem. 266 2004 87 107
38. H. Haikala, and P. Pollesello Calcium sensitivity enhancers IDrugs 3 2000 1199 1205
39. 2 + sensitizer, activates the glibenclamide-sensitive K + channel in rat arterial myocytes Eur. J. Pharmacol. 333 1997 249 259
40. J. Pataricza, J. Hohn, A. Petri, A. Balogh, and J.G. Papp Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein J. Pharm. Pharmacol. 52 2000 213 217
41. P. Kaheinen, P. Pollesello, J. Levijoki, and H. Haikala Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels J. Cardiovasc. Pharmacol. 37 2001 367 374
42. N. Erdei, Z. Papp, P. Pollesello, I. Edes, and Z. Bagi The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles Br. J. Pharmacol. 148 2006 696 702
43. M. Maytin, and W.S. Colucci Cardioprotection: a new paradigm in the management of acute heart failure syndromes Am. J. Cardiol. 96 2005 26G 31G
44. M. Louhelainen, E. Vahtola, P. Kaheinen, H. Leskinen, S. Merasto, V. Kyto, and et al. Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats Br. J. Pharmacol. 150 2007 851 861
45. P. Pollesello, and Z. Papp The cardioprotective effects of levosimendan: preclinical and clinical evidence J. Cardiovasc. Pharmacol. 50 2007 257 263
46. E.F. du Toit, A. Genis, L.H. Opie, P. Pollesello, and A. Lochner A role for the RISK pathway and K(ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart Br. J. Pharmacol. 154 2008 41 50
47. S. Szilágyi, P. Pollesello, J. Levijoki, P. Kaheinen, H. Haikala, I. Edes, and et al. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig Eur. J. Pharmacol. 486 1 Feb 13 2004 67 74
48. 2 +-sensitizing effect but not to stereoselective phosphodiesterase inhibition Basic Clin. Pharmacol. Toxicol. 98 1 Jan 2006 74 78
49. I. Leprán, P. Pollesello, S. Vajda, A. Varró, and J.G. Papp Preconditioning effects of levosimendan in a rabbit cardiac ischemia-reperfusion model J. Cardiovasc. Pharmacol. 48 4 2006 148 152
50. J. Levijoki, P. Pollesello, P. Kaheinen, and H. Haikala Improved survival with simendan after experimental myocardial infarction in rats Eur. J. Pharmacol. 419 2-3 2001 243 248
51. F. Follath, J.G. Cleland, H. Just, J.G. Papp, H. Scholz, K. Peuhkurinen, and et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial Lancet 360 2002 196 202
52. M.T. Slawsky, W.S. Colucci, S.S. Gottlieb, B.H. Greenberg, E. Haeusslein, J. Hare, and et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators Circulation 102 2000 2222 2227
53. M.S. Nieminen, J. Akkila, G. Hasenfuss, F.X. Kleber, L.A. Lehtonen, V. Mitrovic, and et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure J. Am. Coll. Cardiol. 36 2000 1903 1912
54. J. Lilleberg, M.S. Nieminen, J. Akkila, L. Heikkila, A. Kuitunen, L. Lehtonen, and et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting Eur. Heart J. 19 1998 660 668
55. H. Ukkonen, M. Saraste, J. Akkila, J. Knuuti, M. Karanko, H. Iida, and et al. Myocardial efficiency during levosimendan infusion in congestive heart failure Clin. Pharmacol. Ther. 68 2000 522 531
56. M. Packer, W. Colucci, L. Fisher, B.M. Massie, J.R. Teerlink, J. Young, and et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure JCHF 1 2013 103 111
57. A. Mebazaa, M.S. Nieminen, M. Packer, A. Cohen-Solal, F.X. Kleber, S.J. Pocock, and et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial JAMA 297 2007 1883 1891
58. J. Lilleberg, M. Laine, T. Palkama, M. Kivikko, P. Pohjanjousi, and M. Kupari Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure Eur. J. Heart Fail. 9 2007 75 82
59. J.T. Parissis, F. Panou, D. Farmakis, S. Adamopoulos, G. Filippatos, I. Paraskevaidis, and et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure Am. J. Cardiol. 96 3 2005 423 426
60. M. Kivikko, L. Lehtonen, and W.S. Colucci Sustained hemodynamic effects of intravenous levosimendan Circulation 107 2003 81 86
61. A. Mebazaa, M.S. Nieminen, G.S. Filippatos, J.G. Cleland, J.E. Salon, R. Thakkar, and et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE Eur. J. Heart Fail. 11 2009 304 311
62. S.G. Drakos, J.V. Kanakakis, S. Nanas, M. Bonios, E. Kaldara, F. Katsaros, and et al. Intermittent inotropic infusions combined with prophylactic amiodarone for patients with decompensated end-stage heart failure J. Cardiovasc. Pharmacol. 53 2009 157 161
63. M. Kivikko, M.S. Nieminen, P. Pollesello, P. Pohjanjousi, W.S. Colucci, J.R. Teerlink, and et al. The clinical effects of levosimendan are not attenuated by sulfonylureas Scand. Cardiovasc. J. 46 6 Dec 2012 330 338
64. S. Sonntag, S. Sundberg, L.A. Lehtonen, and F.X. Kleber The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia J. Am. Coll. Cardiol. 43 2004 2177 2182
65. M.M. Givertz, C. Andreou, C.H. Conrad, and W.S. Colucci Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation-frequency relationships Circulation 115 2007 1218 1224
66. A. Delaney, C. Bradford, J. McCaffrey, S.M. Bagshaw, and R. Lee Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials Int. J. Cardiol. 138 2010 281 289
67. G. Landoni, G. Biondi-Zoccai, M. Greco, T. Greco, E. Bignami, A. Morelli, and et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies Crit. Care Med. 40 2012 634 646
68. R. Maharaj, and V. Metaxa Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials Crit. Care 15 2011 R140
69. R.W. Harrison, V. Hasselblad, R.H. Mehta, R. Levin, R.A. Harrington, and J.H. Alexander Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis J. Cardiothorac. Vasc. Anesth. 27 6 2013 1224 1232
70. A. Belletti, M.L. Castro, S. Silvetti, T. Greco, G. Biondi-Zoccai, L. Pasin, and et al. The effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials Br. J. Anaesth. 115 5 2015 656 675
71. L. Nagy, Á. Kovács, B. Bódi, E.T. Pásztor, G.Á. Fülöp, A. Tóth, and et al. The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the rat Br. J. Pharmacol. 2015 10.1111/bph.13235 (EPub Aug 4)
72. J.P. Bakkehaug, A.B. Kildal, E.T. Engstad, N. Boardman, T. Næsheim, L. Rønning, and et al. The myosin activator omecamtiv mecarbil increases myocardial oxygen consumption and impairs cardiac efficiency mediated by resting myosin ATPase activity Circ. Heart Fail. 2015 (ePub May 29)
73. J.R. Teerlink, C.P. Clarke, K.G. Saikali, J.H. Lee, M.M. Chen, R.D. Escandon, and et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study Lancet 378 9792 2011 667 675
74. J.R. Teerlink, G.M. Felker, M.M. JJV, P. Ponikowski, M. Metra, G.S. Filippatos, and et al. ATOMIC-AHF: a phase 2 study of intravenous omecamtiv mecarbil, a novel cardiac myosin activator Patients With Acute Heart Failure. The Slide set With the Data Disclosed at the ESC Congress Sept 3 2013 (Amsterdam, is available at www.clinicaltrialresults.org/Slides/ESC%202013/Teerlink-ATOMIC.ppt [accessed on Aug 20, 2015])
75. B.H. Greenberg, W. Chou, K.G. Saikali, R. Escandón, J.H. Lee, M.M. Chen, and et al. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina JACC Heart Fail. 3 1 2015 22 29
76. F. Guarracino, C. Cariello, A. Danella, L. Doroni, F. Lapolla, M. Stefani, and et al. Effect of levosimendan on ventriculo-arterial coupling in patients with ischemic cardiomyopathy Acta Anaesthesiol. Scand. 51 9 Oct 2007 1217 1224
77. S. Masutani, H.J. Cheng, H. Tachibana, W.C. Little, and C.P. Cheng Levosimendan restores the positive force-frequency relation in heart failure Am. J. Physiol. Heart Circ. Physiol. 301 2 2011 H488 H496
78. M.X. Li, and P.M. Hwang Structure and function of cardiac troponin C (TNNC1): implications for heart failure, cardiomyopathies, and troponin modulating drugs Gene Jul 29 2015 10.1016/j.gene.2015.07.074 (pii: S0378-1119(15)00915-4. [Epub ahead of print])
79. P.M. Hwang, and B.D. Sykes Targeting the sarcomere to correct muscle function Nat. Rev. Drug Discov. 14 2015 313 328
80. P. Pollesello Drug discovery and development for acute heart failure drugs: are expectations too high? Int. J. Cardiol. 172 1 2014 11 13